Target intelligence / Profile preview

Neighbor of BRCA1 lncRNA 2 (NBR2)

Target
NBR2
Molecular classification
Long non-coding RNA (lncRNA), Non-protein coding RNA, Other (does not belong to classic families like receptors, enzymes, ion channels, etc.)
01

Overview

NBR2 (Neighbor of BRCA1 lncRNA 2) is a long non-coding RNA gene located adjacent to the tumor suppressor gene BRCA1 on chromosome 17. Unlike its neighboring gene NBR1, which encodes a protein, NBR2 does not code for a functional protein, and its transcripts are instead classified as lncRNAs typically longer than 200 nucleotides. NBR2 is regulated independently from BRCA1 but shares a bi-directional promoter with it. NBR2 is induced in response to glucose starvation and cellular energy stress. It acts as a regulator by directly binding and activating AMP-activated protein kinase (AMPK), promoting energy homeostasis, autophagy, and exerting tumor suppressor functions. Its downregulation is associated with increased tumor proliferation and poor prognosis in several cancers. There is no compelling evidence that NBR2 is directly druggable or a current focus for therapeutics, but it represents a novel example of an lncRNA participating in essential metabolic and oncogenic regulatory pathways.

Other names
NCRNA00192Non-protein coding RNA 192Neighbor of BRCA1 gene 2 (non-protein coding)NBR2 (official abbreviation)
02

Mechanism of action

Not applicable. Since NBR2 is not a therapeutic target for any known drugs, there are no mechanisms of action related to drug interactions. However, at the molecular level, NBR2 directly binds to and activates AMPK, a central metabolic regulator.

03

Biological functions

Regulation of energy stress responseActivation of AMP-activated protein kinase (AMPK)Regulation of autophagyTumor suppressionPossible transcriptional regulation of adjacent BRCA1 gene (context-dependent and not conclusive)
04

Disease associations

Cancer (NBR2 downregulation is observed in several human cancers and is associated with poor prognosis)Potential role in hereditary breast and ovarian cancer syndromes, inferred from co-deletion with BRCA1Glioma susceptibility (from gene-disease association databases)
05

Safety considerations

None directly attributable to targeting NBR2, since it is not a therapeutic target.Manipulation of metabolic pathways via lncRNAs like NBR2 may have broad cellular effects that could pose challenges in therapeutic development
06

Biomarkers

Low NBR2 expression is under investigation as a prognostic biomarker in some cancers, where lower levels correlate with poorer outcomesNot established as a clinical biomarker for patient selection or treatment efficacy

Beyond the preview

Go deeper on Neighbor of BRCA1 lncRNA 2 (NBR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neighbor of BRCA1 lncRNA 2 (NBR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call